Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

EVGN - Evogene Ltd.

IEX Last Trade
1.55
0.100   6.452%

Share volume: 0
Last Updated: Thu 26 Dec 2024 03:24:52 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 4.47%

PREVIOUS CLOSE
CHG
CHG%
$1.45
0.10
6.90%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
5%
Profitability 0%
Dept financing 5%
Liquidity 50%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
7.41%
1 Month
-13.17%
3 Months
-42.23%
6 Months
130.16%
1 Year
66.67%
2 Year
91.12%
Key data
Stock price
$1.55
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.59 - $6.30
52 WEEK CHANGE
$71.70
MARKET CAP 
16.642 M
YIELD 
N/A
SHARES OUTSTANDING 
5.058 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/21/2024
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$62,284
AVERAGE 30 VOLUME 
$59,240
Company detail
CEO: Ofer Haviv
Region: US
Website: evogene.com
Employees: 140
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Evogene Ltd. focuses on product discovery and development in multiple life-science based industries, including human health and agriculture. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer.

Recent news